The current biosimilar landscape - European Medical Journal

The current biosimilar landscape


At the 14th St. Gallen International Breast Cancer Conference 2015, Prof Paul Declerck (KU Leuven, Leuven, Belgium) discusses the understanding of the current state of the biosimilar market as well as on future challenges of the development and regulation of biosimilars.

Biosimilars, which are biological products that demonstrate no clinically meaningful differences to an approved biological product, are currently approved in several areas of the world, and the biosimilars development pipeline is relatively large.

Join our mailing list

To receive the EMJ updates straight to your inbox free of charge, please click the button below.
Join Now